COLLCollegium Pharmaceutical, Inc.
What is the market doing?
The market is leaning against it: in a downtrend (−39% vs 200-day) and heavily shorted (+14% of shares).
In a downtrend, below its 50- and 200-day averages. Price is −39% vs its 200-day average.
Heavily shorted, settled Sep 15, 2026, about a week of normal trading to cover. Down 6.4% since the previous count, up from 13.3% of shares outstanding three months ago.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How COLL is trading
Collegium Pharmaceutical, Inc. is −38% over the past year while the S&P 500 is +18%: 57 points behind the market.
1-year return · S&P 500 +18%
- vs 200-day average
- −39%
vs 200-day average · a clear downtrend
- RSI (14)
- 30
RSI (14) · neutral
- Below its 52-week high
- 56%
Below its 52-week high
Details›
- Last close2026-10-09
- $22.06
- 1 monthS&P 500 +2.7%
- −4.0%
- 1 yearS&P 500 +18%
- −38%
- 5 yearsS&P 500 +88%
- +11%
- vs 50-day average$25.57
- −14%
- 52-week high
- $49.84
- 52-week low
- $21.85
- Annualised volatility
- 42%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- −$629K
| Year | Return |
|---|---|
| 2026 (year to date) | −52% |
| 2025 | +62% |
| 2024 | −6.9% |
| 2023 | +33% |
| 2022 | +24% |
| 2021 | −6.7% |
| 2020 | −2.7% |
| 2019 | +20% |
| 2018 | −7.0% |
| 2017 | +19% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 6 of 10 | +8.4% |
| Feb | 10 | 5 of 10 | +0.12% |
| Mar | 10 | 5 of 10 | −7.9% |
| Apr | 10 | 2 of 10 | −3.4% |
| May | 10 | 3 of 10 | −3.5% |
| Jun | 10 | 6 of 10 | +6.3% |
| Jul | 11 | 6 of 11 | −1.4% |
| Aug | 11 | 5 of 11 | −4.2% |
| Sep | 11 | 4 of 11 | +8.4% |
| Oct | 11 | 5 of 11 | −2.2% |
| Nov | 10 | 8 of 10 | +23% |
| Dec | 10 | 5 of 10 | +1.9% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Drug Manufacturers, Specialty & Generic
Ranks #7 of 41 by RyuScore